• About us
• Contact

Advertisement

Product › Details

CNS drug (neurological drug)

	Next higher product group	pharmaceutical

Record changed: 2024-07-31

Advertisement

More documents for CNS drug (neurological drug)

• [1] Nxera Pharma Co., Ltd.. (9/2/24). "Press Release: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568". Tokyo & Cambridge....
• [2] Vandria S.A.. (8/21/24). "Press Release: Hevolution Foundation and Dolby Family Ventures Join Vandria’s 2nd Series A Closing, Bringing the Total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development". Lausan...
• [3] Addex Therapeutics S.A.. (7/22/24). "Press Release: Addex’s Partner Discontinues ADX71149 Development in Epilepsy". Geneva....
• [4] Merz Therapeutics GmbH. (7/10/24). "Press Release: Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics". Frankfurt a. M.....
• [5] Mission Therapeutics Ltd.. (7/2/24). "Press Release: Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325". Cambridge....
• [6] Addex Therapeutics S.A.. (4/29/24). "Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study". Geneva....
• [7] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
• [8] Merz Therapeutics GmbH. (4/2/24). "Press Release: Merz Enters Asset Purchase Agreement with a US-based Biotech Company". Frankfurt am Main....
• [9] Mission Therapeutics Ltd.. (3/21/24). "Press Release: Mission Therapeutics Commences Landmark Trial of MTX325, a Potential Disease-modifying Treatment for Parkinson’s Disease". Cambridge....
• [10] Engrail Therapeutics, Inc.. (3/19/24). "Press Release: Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies". San Diego, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.